Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’
Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’
View filing at SEC.gov →20 most recent filings and news items mentioning AMGN. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/AMGN/news?limit=20"
Pull AMGN filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayChubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’
View filing at SEC.gov →Citigroup Maintains Neutral on Amgen, Raises Price Target to $405
View filing at SEC.gov →Bernstein Maintains Market Perform on Amgen, Raises Price Target to $345
View filing at SEC.gov →CNBC Halftime Report Final Trades: Amgen, Toast, Chubb
View filing at SEC.gov →BMO Capital Maintains Outperform on Amgen, Raises Price Target to $450
View filing at SEC.gov →Amgen shares are trading higher after the company reported better-than-expected Q2 financial results, raised its FY26 adjusted EPS guidance with its midpoint above estimates and raised its FY26 sales guidance above estimates. Also, BMO Capital maintained its Outperform rating and
View filing at SEC.gov →Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $400
View filing at SEC.gov →RBC Capital Maintains Outperform on Amgen, Raises Price Target to $400
View filing at SEC.gov →Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $450
View filing at SEC.gov →Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $450
View filing at SEC.gov →Truist Securities Maintains Hold on Amgen, Raises Price Target to $362
View filing at SEC.gov →TD Cowen Maintains Buy on Amgen, Raises Price Target to $452
View filing at SEC.gov →UBS Maintains Buy on Amgen, Raises Price Target to $440
View filing at SEC.gov →Amgen Narrows FY2026 GAAP EPS Guidance from $15.62-$17.10 to $15.80-$17.08 vs $15.44 Est
View filing at SEC.gov →Amgen Raises FY2026 Adj EPS Guidance from $21.70-$23.10 to $22.30-$23.50 vs $22.35 Est; Raises FY2026 Sales Guidance from $37.100B-$38.500B to $38.200B-$39.400B vs $37.741B Est
View filing at SEC.gov →Amgen Q2 Adj. EPS $6.29 Beats $5.62 Estimate, Sales $10.054B Beat $9.421B Estimate
View filing at SEC.gov →Amgen Discontinuing Future Development Of AMG 513; To Continue Phase 1 Trial Of AMG 513 In Adults With Obesity
View filing at SEC.gov →Amgen Exec Says Spent $500M In Q2 On Capital Expenditures, Driven By Investments Across U.S. Manufacturing Sites; Continues To Expect Capital Expenditures Of About $2.6B In 2026 To Scale Manufacturing Capacity, Including For Maritide's Launch; Expect A Meaningful Sequential Incre
View filing at SEC.gov →SpaceX Could Swing $204 Billion After Earnings
View filing at SEC.gov →Amgen Identifies Unauthorized Activity In Third-party Cloud Environments In July 2026; Reports No Impact To Products, Operations, Or Financial Reporting From Incident; Reports Exfiltration Of Proprietary And Patient Data From Cloud Environments
View filing at SEC.gov →